A Phase 2b, double blind, randomised, placebo-controlled study of RVT-101 in subjects with dementia with Lewy Bodies | C4C

This is a clinical trial of a study drug called RVT-101 in participants with dementia with Lewy bodies (DLB). DLB is a progressive neurocognitive illness considered to be the second most prevalent cause of degenerative dementia in the elderly population. Currently there are no approved medical treatments for DLB in the EU region. It is believed that patients with DLB have insufficient acetylcholine, a chemical in the brain thought to be responsible for cognition. RVT-101 indirectly promotes the release of this chemical by blocking 5HT6 receptors. Therefore, RVT-101 is being tested in this study to evaluate whether it can help cognition and overall function and to investigate the safety of RVT-101 in participants with dementia with Lewy bodies. Study participation will last approximately 32 weeks. The study will include medical history, physical exams, blood and urine tests, brain imaging, ECGs and questionnaires.